In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients
H De Jonge, H De Loor, K Verbeke… - Clinical …, 2012 - Wiley Online Library
Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow
therapeutic index and highly variable pharmacokinetics. This cross‐sectional study in 59 …
therapeutic index and highly variable pharmacokinetics. This cross‐sectional study in 59 …
[引用][C] In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients
H de Jonge, H de Loor, K Verbeke… - Clinical Pharmacology …, 2012 - cir.nii.ac.jp
In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose
Requirements and Clearance in Renal Transplant Patients | CiNii Research CiNii 国立情報学 …
Requirements and Clearance in Renal Transplant Patients | CiNii Research CiNii 国立情報学 …
In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients
H de Jonge, H de Loor, K Verbeke… - Clinical …, 2012 - pubmed.ncbi.nlm.nih.gov
Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow
therapeutic index and highly variable pharmacokinetics. This cross-sectional study in 59 …
therapeutic index and highly variable pharmacokinetics. This cross-sectional study in 59 …
[引用][C] In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients
H DE JONGE, H DE LOOR… - Clinical …, 2012 - pascal-francis.inist.fr
In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements
and Clearance in Renal Transplant Patients CNRS Inist Pascal-Francis CNRS Pascal and Francis …
and Clearance in Renal Transplant Patients CNRS Inist Pascal-Francis CNRS Pascal and Francis …
In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.
H de Jonge, H de Loor, K Verbeke… - Clinical …, 2012 - europepmc.org
A comment on this article appears in" CYP3A5 genotype, but not CYP3A4* 1b, CYP3A4* 22,
or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients." …
or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients." …